Clinical Trial Update: Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125 [Phase 3]

View source ↗

Summary

A Phase 3 pilot trial evaluated switching HIV patients with central nervous system toxicity from efavirenz to etravirine (TMC125) to assess tolerability and saf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Intelence (Etravirine)
• Sustiva (efavirenz)

Snippet

Sponsor: St Stephens Aids Trust | Conditions: HIV | Phase 3 | Status: COMPLETED